Is a
Patent attributes
Patent Jurisdiction
Patent Number
Date of Patent
March 29, 2022
Patent Application Number
16840249
Date Filed
April 3, 2020
Patent Citations
Patent Primary Examiner
CPC Code
The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
